Gemcitabin HEXAL® 40 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

AstraZeneca AB

Conditions

Advanced Hepatobiliary CancerBiliary Tract CancerGastric CancerGastroesophageal Junction CancerPancreatic Ductal Adenocarcinoma

Phase 1

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

RecruitingCTIS2023-508275-37-00

AstraZeneca ABBiliary Tract Cancer, Gastric Cancer, Gastroesophageal Junction Cancer +1

Start: 2024-11-11Target: 9Updated: 2026-01-14

Phase 2

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

RecruitingCTIS2022-502317-29-00

AstraZeneca ABAdvanced Hepatobiliary Cancer

Start: 2023-07-12Target: 60Updated: 2025-12-11